Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Access Pharmaceuticals Provides Update On ProLindac(TM) Phase 2 Ovarian Cancer Trial And Clinical Development Plan
ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP), provided an update on the progress in the Company"s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies. Access recently announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this study, 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access plans to conduct several combination trials in different solid tumor types both as Company-sponsored trials and in conjunction with its two previously announced co-development partners.
generic viagra online
Acute Stroke Centres Promise To 'revolutionise' Stroke Care Services
The growth of acute stroke care centres and systems of care could revolutionise clinicians" ability to treat patients with stroke, according to an analysis of services published ahead of print in the Journal of NeuroInterventional Surgery.
News of the day
WHO May Declare Pandemic As Swine Flu Surges In Australia
World Health Organization officials are meeting today to discuss the world swine flu situation and are expected to decide to move the pandemic
Diagnostics

Merck Seeks European License For Cladribine for relapsing remitting MS

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington. If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS. Multiple Scleroris Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009